2008-A APPLICATION OF LIVERFAST BIOMARKERS TO PREDICT STEATOSIS IN CHRONIC HEPATITIS B PATIENTS WITH METABOLIC SYNDROME Mati Ullah Dad Ullah 1 , Mansoor Rahman 1 , Mehdi Sakka 2 , Rana Alkouri 2 , Muhammad Asad Raza 1 , Mukarram Jamat Ali 1 , Karen Campoverde Reyes 1 , Maxime Deregnaucourt 2 , Dominique Bonnefont-Rousselot 2,3 , Ronald Quiambao 4 , Mona Munteanu 4 and Daryl T
Sent to your pharmacy
If you stop treatment without ongoing support, you may see some weight come back
In addition, a meta-analysis of 1193 patients with baseline SGLT2i use in AMPLITUDE-O and Harmony Outcomes revealed an HR for MACE of 0.78 (95% CI 0.491.24) with SGLT2is and 0.77 (95% CI 0.680.87) without SGLT2is ( P -value for interaction 0.95), and an HR for HHF of 0.34 (95% CI 0.120.96) with SGLT2is and 0.72 (95% CI 0.550.92) without SGLT2is ( P -value for interaction 0.18) [48]
This is a genuine medical assessment, not a rubber stamp